Characterization of human IgG antimouse antibody in patients with B-cell malignancies

Gerald L Denardo, Gary R. Mirick, Linda A. Kroger, Bonnie M. Bradt, Kathleen R. Lamborn, Sally J. DeNardo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: Immunotherapeutic approaches to cancer offer an attractive adjunct to conventional modalities, although human antiglobulin responses can be an obstacle to repeated treatment. This study of a large number of patients with B-cell malignancies, over an extended period of time, characterized their human antimouse antibody (HAMA) seroconversion. Experimental Design: A total of 617 samples from 112 subjects were analyzed for HAMA titers. Eighty-five patients with B-cell malignancies; 12 breast cancer patients, and 15 volunteers were titered for comparison. Fifty-six B-cell malignancy patients were titered for HAMA throughout Lym-1 radioimmunotherapy (RIT); 29 were titered after a single imaging dose of Lym-1 antibody. Results: Baseline titers did not correlate with subsequent HAMA seroconversion against Lym-1. Only 1 of 29 (3%) of the patients developed HAMA after an imaging dose of Lym-1. Of the RIT trial group, 37 of 56 (66%) never developed HAMA above baseline despite multiple doses. Of those who did (19 of 56; or 34%), the HAMA responses fell into two categories. Thirteen responded rapidly (median of 31 days) and were termed "early responders," whereas 6, termed "late responders," had a median response time of 111 days. Early responders developed higher peak HAMA titers with fewer exposures to Lym-1 and took longer to return to baseline than did the late responders. The frequency of new antiglobulin seroconversion decreased as the number of exposures increased. Conclusions: Seventy-seven percent of B-cell malignancy patients developed no response or a weak response after multiple doses of mouse Lym-1 antibody. Positive responders occurred in all histology types and fell into two categories differing in seroconversion time and titer, possibly indicative of the initial state of the immune system.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume9
Issue number10 II
StatePublished - Oct 1 2003

Fingerprint

B-Lymphocytes
Immunoglobulin G
Antibodies
Neoplasms
Radioimmunotherapy
Anti-Idiotypic Antibodies
Reaction Time
Antibody Formation
Volunteers
Immune System
Histology
Research Design
Breast Neoplasms
Seroconversion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Denardo, G. L., Mirick, G. R., Kroger, L. A., Bradt, B. M., Lamborn, K. R., & DeNardo, S. J. (2003). Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clinical Cancer Research, 9(10 II).

Characterization of human IgG antimouse antibody in patients with B-cell malignancies. / Denardo, Gerald L; Mirick, Gary R.; Kroger, Linda A.; Bradt, Bonnie M.; Lamborn, Kathleen R.; DeNardo, Sally J.

In: Clinical Cancer Research, Vol. 9, No. 10 II, 01.10.2003.

Research output: Contribution to journalArticle

Denardo, GL, Mirick, GR, Kroger, LA, Bradt, BM, Lamborn, KR & DeNardo, SJ 2003, 'Characterization of human IgG antimouse antibody in patients with B-cell malignancies', Clinical Cancer Research, vol. 9, no. 10 II.
Denardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clinical Cancer Research. 2003 Oct 1;9(10 II).
Denardo, Gerald L ; Mirick, Gary R. ; Kroger, Linda A. ; Bradt, Bonnie M. ; Lamborn, Kathleen R. ; DeNardo, Sally J. / Characterization of human IgG antimouse antibody in patients with B-cell malignancies. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 10 II.
@article{26fa73446b6941cdb67e020043f3e57f,
title = "Characterization of human IgG antimouse antibody in patients with B-cell malignancies",
abstract = "Purpose: Immunotherapeutic approaches to cancer offer an attractive adjunct to conventional modalities, although human antiglobulin responses can be an obstacle to repeated treatment. This study of a large number of patients with B-cell malignancies, over an extended period of time, characterized their human antimouse antibody (HAMA) seroconversion. Experimental Design: A total of 617 samples from 112 subjects were analyzed for HAMA titers. Eighty-five patients with B-cell malignancies; 12 breast cancer patients, and 15 volunteers were titered for comparison. Fifty-six B-cell malignancy patients were titered for HAMA throughout Lym-1 radioimmunotherapy (RIT); 29 were titered after a single imaging dose of Lym-1 antibody. Results: Baseline titers did not correlate with subsequent HAMA seroconversion against Lym-1. Only 1 of 29 (3{\%}) of the patients developed HAMA after an imaging dose of Lym-1. Of the RIT trial group, 37 of 56 (66{\%}) never developed HAMA above baseline despite multiple doses. Of those who did (19 of 56; or 34{\%}), the HAMA responses fell into two categories. Thirteen responded rapidly (median of 31 days) and were termed {"}early responders,{"} whereas 6, termed {"}late responders,{"} had a median response time of 111 days. Early responders developed higher peak HAMA titers with fewer exposures to Lym-1 and took longer to return to baseline than did the late responders. The frequency of new antiglobulin seroconversion decreased as the number of exposures increased. Conclusions: Seventy-seven percent of B-cell malignancy patients developed no response or a weak response after multiple doses of mouse Lym-1 antibody. Positive responders occurred in all histology types and fell into two categories differing in seroconversion time and titer, possibly indicative of the initial state of the immune system.",
author = "Denardo, {Gerald L} and Mirick, {Gary R.} and Kroger, {Linda A.} and Bradt, {Bonnie M.} and Lamborn, {Kathleen R.} and DeNardo, {Sally J.}",
year = "2003",
month = "10",
day = "1",
language = "English (US)",
volume = "9",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10 II",

}

TY - JOUR

T1 - Characterization of human IgG antimouse antibody in patients with B-cell malignancies

AU - Denardo, Gerald L

AU - Mirick, Gary R.

AU - Kroger, Linda A.

AU - Bradt, Bonnie M.

AU - Lamborn, Kathleen R.

AU - DeNardo, Sally J.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Purpose: Immunotherapeutic approaches to cancer offer an attractive adjunct to conventional modalities, although human antiglobulin responses can be an obstacle to repeated treatment. This study of a large number of patients with B-cell malignancies, over an extended period of time, characterized their human antimouse antibody (HAMA) seroconversion. Experimental Design: A total of 617 samples from 112 subjects were analyzed for HAMA titers. Eighty-five patients with B-cell malignancies; 12 breast cancer patients, and 15 volunteers were titered for comparison. Fifty-six B-cell malignancy patients were titered for HAMA throughout Lym-1 radioimmunotherapy (RIT); 29 were titered after a single imaging dose of Lym-1 antibody. Results: Baseline titers did not correlate with subsequent HAMA seroconversion against Lym-1. Only 1 of 29 (3%) of the patients developed HAMA after an imaging dose of Lym-1. Of the RIT trial group, 37 of 56 (66%) never developed HAMA above baseline despite multiple doses. Of those who did (19 of 56; or 34%), the HAMA responses fell into two categories. Thirteen responded rapidly (median of 31 days) and were termed "early responders," whereas 6, termed "late responders," had a median response time of 111 days. Early responders developed higher peak HAMA titers with fewer exposures to Lym-1 and took longer to return to baseline than did the late responders. The frequency of new antiglobulin seroconversion decreased as the number of exposures increased. Conclusions: Seventy-seven percent of B-cell malignancy patients developed no response or a weak response after multiple doses of mouse Lym-1 antibody. Positive responders occurred in all histology types and fell into two categories differing in seroconversion time and titer, possibly indicative of the initial state of the immune system.

AB - Purpose: Immunotherapeutic approaches to cancer offer an attractive adjunct to conventional modalities, although human antiglobulin responses can be an obstacle to repeated treatment. This study of a large number of patients with B-cell malignancies, over an extended period of time, characterized their human antimouse antibody (HAMA) seroconversion. Experimental Design: A total of 617 samples from 112 subjects were analyzed for HAMA titers. Eighty-five patients with B-cell malignancies; 12 breast cancer patients, and 15 volunteers were titered for comparison. Fifty-six B-cell malignancy patients were titered for HAMA throughout Lym-1 radioimmunotherapy (RIT); 29 were titered after a single imaging dose of Lym-1 antibody. Results: Baseline titers did not correlate with subsequent HAMA seroconversion against Lym-1. Only 1 of 29 (3%) of the patients developed HAMA after an imaging dose of Lym-1. Of the RIT trial group, 37 of 56 (66%) never developed HAMA above baseline despite multiple doses. Of those who did (19 of 56; or 34%), the HAMA responses fell into two categories. Thirteen responded rapidly (median of 31 days) and were termed "early responders," whereas 6, termed "late responders," had a median response time of 111 days. Early responders developed higher peak HAMA titers with fewer exposures to Lym-1 and took longer to return to baseline than did the late responders. The frequency of new antiglobulin seroconversion decreased as the number of exposures increased. Conclusions: Seventy-seven percent of B-cell malignancy patients developed no response or a weak response after multiple doses of mouse Lym-1 antibody. Positive responders occurred in all histology types and fell into two categories differing in seroconversion time and titer, possibly indicative of the initial state of the immune system.

UR - http://www.scopus.com/inward/record.url?scp=0141456526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141456526&partnerID=8YFLogxK

M3 - Article

VL - 9

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10 II

ER -